Abstract | OBJECTIVE: METHODS: Flow cytometric and in vitro functional analyses of peripheral blood mononuclear cells from 12 patients receiving 5 daily intravenous infusions of CD5 Plus at doses of 0.20 or 0.33 mg/kg were performed before, during and after treatment. RESULTS: Peripheral CD3+ T cells were significantly depleted (p < 0.01) during treatment on Days 2 and 5 and returned towards baseline on Days 15 to 29; changes in CD5+ B cells occurred in parallel. There was no significant treatment effect on monocytes. All T cell subsets examined, including CD4, CD8, CD45RA, CD45RO, HLA-DR+, TCR-alpha beta and TCR-gamma delta, were affected equally through Day 15. On Day 29, the median CD4:CD8 ratio, elevated before treatment, was significantly decreased (p < 0.01), approaching the ratio observed in healthy controls. Proliferative responses to antigenic, allogeneic and mitogenic stimuli in vitro were depressed but detectable during the time of maximal T cell depletion and normalized to baseline values with recovery of T cell number. Spontaneous and pokeweed mitogen induced immunoglobulin secretion were unaffected in these patients. CONCLUSION: Treatment associated effects of CD5 Plus were observed for both T and B cell populations which bear the CD5 antigen, and were reversible, as measured by in vitro assays of immune cell function, phenotype and number.
|
Authors | D M Fishwild, V Strand |
Journal | The Journal of rheumatology
(J Rheumatol)
Vol. 21
Issue 4
Pg. 596-604
(Apr 1994)
ISSN: 0315-162X [Print] Canada |
PMID | 7518519
(Publication Type: Clinical Trial, Clinical Trial, Phase II, Journal Article)
|
Chemical References |
- Antibodies, Monoclonal
- Antigens, CD
- CD5 Antigens
- Immunoglobulin G
- Immunotoxins
- Receptors, IgG
- Ricin
|
Topics |
- Adult
- Antibodies, Monoclonal
(therapeutic use)
- Antigens, CD
- Arthritis, Rheumatoid
(blood, immunology, therapy)
- B-Lymphocyte Subsets
(drug effects, immunology)
- CD5 Antigens
- Cytotoxicity, Immunologic
(drug effects)
- Female
- Humans
- Immunoglobulin G
(therapeutic use)
- Immunotoxins
(therapeutic use)
- In Vitro Techniques
- Leukocyte Count
- Male
- Middle Aged
- Phenotype
- Receptors, IgG
(metabolism)
- Ricin
(therapeutic use)
- T-Lymphocyte Subsets
(drug effects, immunology)
|